Minneapolis, MN – According to filings with the U.S. Securities and Exchange Commission, Vergent Bioscience is raising $22,090,063.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, John Santini played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Vergent Bioscience
At Vergent Bioscience our molecularly-targeted imaging molecule, VGT-309, binds to enzymes that are overexpressed in tumor tissue, activating a brightly fluorescing dye. This proprietary molecule can identify and bind to multiple cancers including lung, breast, ovarian, colorectal, and brain, among others. When injected prior to surgery, VGT-309 lights up cancerous tissue and gives the surgeon a clear visual guide for the removal procedure. Vergents approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic surgery procedures, while uniquely retaining the pricing flexibility required for success in a value-based healthcare system.

To learn more about Vergent Bioscience, visit http://www.vergentbio.com/

Contact:
John Santini, President and Chief Executive Officer
952-479-7496
https://www.linkedin.com/in/john-santini-6264011/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved